We have developed PEG-DI, an agent designed to block binding of pathogenic aPL to β2GPI, and have shown that it is effective at blocking the effects of APS-IgG in three different assays, two in-vitro and one in-vivo. The gene discussed is APOH; the disease is autoimmune polyendocrinopathy.